Summary

Eligibility
for people ages 45-90 (full criteria)
Location
at Sausalito, California
Dates
study started
estimated completion
Principal Investigator
by Dean OrnishKim Norman, MD
Photo of Kim Norman
Kim Norman

Description

Summary

The objective of this study is to determine if comprehensive lifestyle changes may slow, stop, or reverse the progression of early-stage Alzheimer's disease.

Official Title

Lifestyle Intervention for Early Alzheimer's Disease

Details

100 patients who have early Alzheimer's disease (MoCA above 17) in the San Francisco Bay area are being enrolled over time and are randomly assigned to one of two groups. After baseline testing, the first group then receives this lifestyle medicine program for 20 weeks, four hours/day, three days/week (all done virtually via Zoom since March 2020 due to COVID-19). The second group will not receive the lifestyle program for 20 weeks and will serve as a randomized control group during this phase of the study. Both groups will be re-tested after 20 weeks. Then, the second group will "cross over" and receive this lifestyle medicine program for 20 weeks and the first group will continue the lifestyle program for 20 additional weeks. After a total of 40 weeks, both groups will be re-tested again and compared. Those initially randomly assigned to the control group will receive the intervention for 40 weeks and then be re-tested at that time. The intervention may be extended beyond 40 weeks.

Keywords

Alzheimer Disease Mild Cognitive Impairment Lifestyle medicine

Eligibility

You can join if…

Open to people ages 45-90

  • Current diagnosis of mild dementia or mild cognitive impairment due to Alzheimer's disease/process, with MoCA score above 17 (i.e., 18 or higher)
  • Willingness and ability to participate in all aspects of the intervention
  • Availability of spouse or caregiver who can provide collateral information and assist with study adherence
  • PET scans and/or C2N testing will be performed at baseline if there is any doubt about the clinical diagnosis of Alzheimer's disease

You CAN'T join if...

  • severe dementia
  • physical disability that precludes regular exercise
  • clear evidence for other causes of neurodegeneration or dementia, e.g., severe cerebrovascular disease, Parkinson's disease
  • significant ongoing psychiatric or substance abuse problems

Location

  • Dean Ornish, M.D. accepting new patients
    Sausalito California 94965 United States

Lead Scientists at UCSF

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Preventive Medicine Research Institute
ID
NCT04606420
Phase
Phase 2
Study Type
Interventional
Last Updated